212 related articles for article (PubMed ID: 23521018)
21. Strengths and weaknesses of current polio vaccines--a view from industry.
André FE
Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338
[TBL] [Abstract][Full Text] [Related]
22. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation.
Thompson KM; Tebbens RJ
Expert Rev Vaccines; 2012 Apr; 11(4):449-59. PubMed ID: 22551030
[TBL] [Abstract][Full Text] [Related]
23. Update on vaccine-derived polioviruses.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(40):1093-7. PubMed ID: 17035927
[TBL] [Abstract][Full Text] [Related]
24. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
Chowdhary R; Dhole TN
J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
[TBL] [Abstract][Full Text] [Related]
25. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
26. Sabin and wild polioviruses from apparently healthy primary school children in northeastern Nigeria.
Baba MM; Oderinde BS; Patrick PZ; Jarmai MM
J Med Virol; 2012 Feb; 84(2):358-64. PubMed ID: 22170559
[TBL] [Abstract][Full Text] [Related]
27. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
[TBL] [Abstract][Full Text] [Related]
28. Implications of a circulating vaccine-derived poliovirus in Nigeria.
Jenkins HE; Aylward RB; Gasasira A; Donnelly CA; Mwanza M; Corander J; Garnier S; Chauvin C; Abanida E; Pate MA; Adu F; Baba M; Grassly NC
N Engl J Med; 2010 Jun; 362(25):2360-9. PubMed ID: 20573924
[TBL] [Abstract][Full Text] [Related]
29. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
Friedrich F
Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702
[TBL] [Abstract][Full Text] [Related]
30. Circulating vaccine derived polio viruses and their impact on global polio eradication.
Wagner BG; Earn DJ
Bull Math Biol; 2008 Jan; 70(1):253-80. PubMed ID: 17934778
[TBL] [Abstract][Full Text] [Related]
31. Polio eradication: the OPV paradox.
Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
[TBL] [Abstract][Full Text] [Related]
32. World wide experience with inactivated poliovirus vaccine.
Bonnet MC; Dutta A
Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology of poliomyelitis--options and update.
Dutta A
Vaccine; 2008 Oct; 26(45):5767-73. PubMed ID: 18755232
[TBL] [Abstract][Full Text] [Related]
34. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
[TBL] [Abstract][Full Text] [Related]
35. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
Pliaka V; Kyriakopoulou Z; Markoulatos P
Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
[TBL] [Abstract][Full Text] [Related]
36. A vision of a world without polio: the OPV cessation strategy.
Heymann DL; Sutter RW; Aylward RB
Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
[TBL] [Abstract][Full Text] [Related]
37. The potential impact of expanding target age groups for polio immunization campaigns.
Duintjer Tebbens RJ; Kalkowska DA; Wassilak SG; Pallansch MA; Cochi SL; Thompson KM
BMC Infect Dis; 2014 Jan; 14():45. PubMed ID: 24472313
[TBL] [Abstract][Full Text] [Related]
38. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel.
Swartz TA; Green MS; Handscher R; Sofer D; Cohen-Dar M; Shohat T; Habib S; Barak E; Dror Z; Somekh E; Peled-Leviathan T; Yulzari R; Libling A; Mendelson E; Shulman LM
Vaccine; 2008 Feb; 26(8):1083-90. PubMed ID: 18241962
[TBL] [Abstract][Full Text] [Related]
39. [End phase challenges of poliomyelitis eradication programme realization].
Jarzabek Z
Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
[TBL] [Abstract][Full Text] [Related]
40. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India.
Grassly NC; Jafari H; Bahl S; Sethi R; Deshpande JM; Wolff C; Sutter RW; Aylward RB
J Infect Dis; 2012 May; 205(10):1554-61. PubMed ID: 22448007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
